Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas Journal Article
| Authors: | Iwamoto, F. M.; Hottinger, A. F.; Karimi, S.; Riedel, E.; Dantis, J.; Jahdi, M.; Panageas, K. S.; Lassman, A. B.; Abrey, L. E.; Fleisher, M.; Deangelis, L. M.; Holland, E. C.; Hormigo, A. |
| Article Title: | Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas |
| Abstract: | The objective of this study was to evaluate if longitudinal measurements of serum matrix metalloproteinase-9 (MMP-9) correlated with disease status or survival in adults with gliomas. Serum samples were collected prospectively and concurrently with MRI scans at multiple time points during the course of the disease. MMP-9 levels were determined by ELISA and correlated with radiographic disease status and survival. Forty-one patients with low-grade gliomas, 105 with anaplastic gliomas, and 197 with glioblastoma enrolled in this study from August 2002 to September 2008. A total of 1,684 serum samples (97.1% of all MMP-9 samples) had a matching MRI scan. No statistically significant association was observed between levels of serum MMP-9 and radiographic disease status in low-grade gliomas (P = 0.98), anaplastic gliomas (P = 0.39) or glioblastomas (P = 0.33). Among patients with glioblastoma, longitudinal increases in MMP-9 had a weak association with shorter survival (HR = 1.1 per each doubling in MMP-9 levels, 95% CI, 1.0-1.3, P = 0.04) but they were not independently associated with survival when adjusted for age, extent of resection, and performance status. Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival. © 2011 Springer Science+Business Media, LLC. |
| Keywords: | adult; cancer survival; controlled study; major clinical study; disease course; conference paper; disease marker; temozolomide; nuclear magnetic resonance imaging; glioma; brain neoplasms; cancer grading; prospective study; prospective studies; proportional hazards models; gelatinase b; tumor markers, biological; tumor marker; survival time; longitudinal studies; glioblastoma; enzyme-linked immunosorbent assay; chemoradiotherapy; longitudinal study; matrix metalloproteinase-9; kaplan-meier estimate; enzyme blood level; matrix metalloproteinase 9; serum marker |
| Journal Title: | Journal of Neuro-Oncology |
| Volume: | 105 |
| Issue: | 3 |
| ISSN: | 0167-594X |
| Publisher: | Springer |
| Date Published: | 2011-12-01 |
| Start Page: | 607 |
| End Page: | 612 |
| Language: | English |
| DOI: | 10.1007/s11060-011-0628-z |
| PROVIDER: | scopus |
| PUBMED: | 21710351 |
| PMCID: | PMC7398421 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 January 2012" - "CODEN: JNODD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work